“Those of us in the melanoma business have felt like we ... specifically inhibits the V600E mutant BRAF, a constitutively active kinase present in more than half of metastatic melanomas.

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

In this study, 49 of 55 patients enrolled in the dose escalation portion of the study had metastatic melanoma. Furthermore, there was enrichment for patients with V600E BRAF mutations, as many ...

Melanoma's ability to upregulate prosurvival ... This is especially the case with BRAF inhibitors such as vemurafenib. Studies have shown that treating with BRAF inhibitors in the setting of ...

Cemsidomide: Cemsidomide is an oral degrader of IKZF1/3 for the potential treatment of relapsed/refractory (R/R) multiple myeloma (MM) and R/R non-Hodgkin’s lymphoma (NHL).